Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice

被引:10
|
作者
Kroon, Tori [1 ]
Bhadouria, Neharika [2 ]
Niziolek, Paul [3 ]
Edwards, Daniel, III [4 ]
Choi, Roy [5 ]
Clinkenbeard, Erica L. [4 ]
Robling, Alexander [4 ,5 ]
Holguin, Nilsson [4 ,5 ,6 ]
机构
[1] IUPUI, Dept Biomed Engn, Indianapolis, IN USA
[2] Purdue Univ, Dept Mech Engn, W Lafayette, IN 47907 USA
[3] IUPUI, Radiol & Imaging Sci, Indianapolis, IN USA
[4] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA
[5] IUPUI, Dept Anat & Cell Biol, Indianapolis, IN USA
[6] IUPUI, Dept Mech & Energy Engn, Indianapolis, IN USA
关键词
ANABOLIC THERAPEUTICS; CHONDROCYTE AND CARTILAGE BIOLOGY; GENETIC ANIMAL MODELS; PRECLINICAL STUDIES; WNT/beta-CATENIN/LRPs; BONE-FORMATION; NEGATIVE REGULATOR; NOTOCHORDAL CELL; SCLEROSTIN; WNT; ACTIVATION; EXPRESSION; DKK1;
D O I
10.1002/jbmr.4546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intervertebral disc (IVD) degeneration is a leading cause of low back pain, characterized by accelerated extracellular matrix breakdown and IVD height loss, but there is no approved pharmacological therapeutic. Deletion of Wnt ligand competitor Lrp5 induces IVD degeneration, suggesting that Wnt signaling is essential for IVD homeostasis. Therefore, the IVD may respond to neutralization of Wnt ligand competitors sost(gene)/sclerostin(protein) and/or dickkopf-1 (dkk1). Anti-sclerostin antibody (scl-Ab) is an FDA-approved bone therapeutic that activates Wnt signaling. We aimed to (i) determine if pharmacological neutralization of sclerostin, dkk1, or their combination would stimulate Wnt signaling and augment IVD structure and (ii) determine the prolonged adaptation of the IVD to global, persistent deletion of sost. Nine-week-old C57Bl/6J female mice (n - 6-7/group) were subcutaneously injected 2x/week for 5.5 weeks with scl-Ab (25 mg/kg), dkk1-Ab (25 mg/kg), 3:1 scl-Ab/dkk1-Ab (18.75:6.25 mg/kg), or vehicle (veh). Separately, IVD of sost KO and wild-type (WT) mice (n - 8/group) were harvested at 16 weeks of age. First, compared with vehicle, injection of scl-Ab, dkk1-Ab, and 3:1 scl-Ab/dkk1-Ab similarly increased lumbar IVD height and beta-catenin gene expression. Despite these similarities, only injection of scl-Ab alone strengthened IVD mechanical properties and decreased heat shock protein gene expressions. Genetically and compared with WT, sost KO enlarged IVD height, increased proteoglycan staining, and imbibed IVD hydration. Notably, persistent deletion of sost was compensated by upregulation of dkk1, which consequently reduced the cell nuclear fraction for Wnt signaling co-transcription factor beta-catenin in the IVD. Lastly, RNA-sequencing pathway analysis confirmed the compensatory suppression of Wnt signaling and revealed a reduction of cellular stress-related pathways. Together, suppression of sost/sclerostin or dkk1 each augmented IVD structure by stimulating Wnt signaling, but scl-Ab outperformed dkk1-Ab in strengthening the IVD. Ultimately, postmenopausal women prescribed scl-Ab injections to prevent vertebral fracture may also benefit from a restoration of IVD height and health. (C) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
引用
收藏
页码:1156 / 1169
页数:14
相关论文
共 50 条
  • [21] Serum Levels of Sclerostin and dickkopf-1 in Geriatric Patients with Osteoporotic Hip Fractures
    Pietschmann, Peter
    Dorfer, Sonja
    Kapfenberger, Andrea
    Foeger-Samwald, Ursula
    Kudlacek, Stefan
    Dovjak, Peter
    Pietschmann, Peter
    Pietschmann, Peter
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [22] Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
    Ozbek, Ayse Elverdi
    Korkmaz, Huseyin
    Sozen, Mehmet
    Ipekci, Suleyman Hilmi
    Abusoglu, Sedat
    Kirac, Cem Onur
    Unlu, Ali
    Kebapcilar, Levent
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2024, 39 (01) : 130 - 135
  • [23] Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
    Stergios A. Polyzos
    Athanasios D. Anastasilakis
    Jannis Kountouras
    Polyzois Makras
    Athanasios Papatheodorou
    Panagiotis Kokkoris
    Grigorios T. Sakellariou
    Evangelos Terpos
    Journal of Bone and Mineral Metabolism, 2016, 34 : 447 - 456
  • [24] Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1
    Tsourdi, Elena
    Rijntjes, Eddy
    Koehrle, Josef
    Hofbauer, Lorenz C.
    Rauner, Martina
    ENDOCRINOLOGY, 2015, 156 (10) : 3517 - 3527
  • [25] Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine
    Masafumi Kashii
    Yohei Matuso
    Tsuyoshi Sugiura
    Takahito Fujimori
    Yukitaka Nagamoto
    Takahiro Makino
    Takashi Kaito
    Kosuke Ebina
    Motoki Iwasaki
    Hideki Yoshikawa
    Journal of Bone and Mineral Metabolism, 2016, 34 : 315 - 324
  • [26] Serum Levels of Sclerostin and Dickkopf-1: Effects of Age, Gender and Fracture Status
    Dovjak, Peter
    Dorfer, Sonja
    Foeger-Samwald, Ursula
    Kudlacek, Stefan
    Marculescu, Rodrig
    Pietschmann, Peter
    GERONTOLOGY, 2014, 60 (06) : 493 - 501
  • [27] Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
    Ayşe Elverdi Özbek
    Hüseyin Korkmaz
    Mehmet Sözen
    Süleyman Hilmi İpekçi
    Sedat Abuşoğlu
    Cem Onur Kıraç
    Ali Ünlü
    Levent Kebapçılar
    Indian Journal of Clinical Biochemistry, 2024, 39 : 130 - 135
  • [28] New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1)
    Dincel, Aylin Sepinci
    Jorgensen, Niklas Rye
    CALCIFIED TISSUE INTERNATIONAL, 2023, 112 (02) : 243 - 257
  • [29] Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
    Gerov, Vladimir
    Gerova, Daniela
    Micheva, Ilina
    Nikolova, Miglena
    Mihaylova, Galya
    Galunska, Bistra
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [30] GENETIC STUDIES ON DICKKOPF-1, SCLEROSTIN AND THE SEVERITY OF JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS
    de Rooy, D.
    Yeremenko, N.
    Knevel, R.
    Brouwer, E.
    Wilson, G.
    Lindqvist, E.
    Saxne, T.
    Krabben, A.
    Leijsma, M.
    Tsonaka, R.
    Daha, N.
    Zhernakova, S.
    Houwing-Duistermaat, J.
    Huizinga, T.
    Baeten, D.
    Toes, R.
    van der Helm-van Mil, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 83 - 83